Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Recro Pharma (REPH) Stock Price

Media headlines about Recro Pharma (NASDAQ:REPH) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 47.5514882747837 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several equities research analysts have recently commented on REPH shares. Zacks Investment Research downgraded Recro Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price objective on shares of Recro Pharma in a report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Recro Pharma presently has a consensus rating of “Buy” and an average target price of $11.65.

Recro Pharma (NASDAQ REPH) traded down $0.02 during midday trading on Friday, hitting $9.73. The stock had a trading volume of 46,251 shares, compared to its average volume of 134,108. The firm has a market cap of $185.69, a P/E ratio of -4.53 and a beta of -0.50. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.59.

In other news, major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $9.58, for a total value of $2,132,661.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 814,050 shares of company stock valued at $7,861,016. 21.60% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Recro Pharma (REPH) Stock Price” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit